(Test Bank) Pharmacotherapeutics for Nurse Practitioner Prescribers

Woo, 3

Nursing

Test Bank

3rd Edition

• $10.00 $35.00

---

Description

Test Bank for Pharmacotherapeutics for Nurse Practitioner Prescribers, The downloadable file consists of 160 pages, and the total size of the file is 1.55 MB. Purchase now only for highly discounted price.

Author(s): Woo

---

---

Study Note Preview

Chapter i1: iThe iRole iof ithe iNurse iPractitioner ias iPrescriber Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. iNurse ipractitioner iprescriptive iauthority iis iregulated iby: A. The iNational iCouncil iof iState iBoards iof iNursing B. The iU.S. iDrug iEnforcement iAdministration C. The iState iBoard iof iNursing ifor ieach istate D. The iState iBoard iof iPharmacy _ 2. iPhysician iAssistant i(PA) iprescriptive iauthority iis iregulated iby: A. The iNational iCouncil iof iState iBoards iof iNursing B. The iU.S. iDrug iEnforcement iAdministration C. The iState iBoard iof iNursing D. The iState iBoard iof iMedical iExaminers _ 3. iClinical ijudgment iin iprescribing iincludes: A. Factoring iin ithe icost ito ithe ipatient iof ithe imedication iprescribed B. Always iprescribing ithe inewest imedication iavailable ifor ithe idisease iprocess C. Handing iout idrug isamples ito ipoor ipatients D. Prescribing iall igeneric imedications ito icut icosts _ 4. iCriteria ifor ichoosing ian ieffective idrug ifor ia idisorder iinclude: A. Asking ithe ipatient iwhat idrug ithey ithink iwould iwork ibest ifor ithem B. Consulting inationally irecognized iguidelines ifor idisease imanagement C. Prescribing imedications ithat iare iavailable ias isamples ibefore iwriting ia iprescription D. Following iU.S. iDrug iEnforcement iAdministration i(DEA) iguidelines ifor iprescribing _ 5. iNurse ipractitioner ipractice imay ithrive iunder ihealth -care ireform idue ito: A. The idemonstrated iability iof inurse ipractitioners ito icontrol icosts iand iimprove ipatient ioutcomes B. The ifact ithat inurse ipractitioners iwill ibe iable ito ipractice iindependently C. The ifact ithat inurse ipractitioners iwill ihave ifull ireimbursement iunder ihealth - care ireform D. The iability ito ishift iaccountability ifor iMedicaid ito ithe istate ilevel Chapter i1: iThe iRole iof ithe iNurse iPractitioner ias iPrescriber iAnswer iSection MULTIPLE iCHOICE 1. ANS: iC PTS: i i i1 2. ANS: iD PTS: i i i1 3. ANS: iA PTS: i i i1 4. ANS: iB PTS: i i i1 5. ANS: iA PTS: i i i1 Chapter i2: iReview iof iBasic iPrinciples iof iPharmacology Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. iA ipatient’s inutritional iintake iand ilab iwork ireflects ihypoalbuminemia. iThis iis icritical ito iprescribing ibecause: A. Distribution iof idrugs ito itarget itissue imay ibe iaffected B. The isolubility iof ithe idrug iwill inot imatch ithe isite iof iabsorption C. There iwill ibe iless ifree idrug iavailable ito igenerate ian ieffect D. Drugs ibound ito ialbumin iare ireadily iexcreted iby ithe ikidney _ 2. iDrugs ithat ihave ia isignificant ifirst-pass ieffect: A. Must ibe igiven iby ithe ienteral i(oral) iroute ionly B. Bypass ithe ihepatic icirculation C. Are irapidly imetabolized iby ithe iliver iand imay ihave ilittle iif iany idesired iaction D. Are iconverted iby ithe iliver ito imore iactive iand ifat-soluble iforms _ 3. iThe iroute iof iexcretion iof ia ivolatile idrug iwill ilikely ibe: A. The ikidneys B. The ilungs C. The ibile iand ifeces D. The iskin _ 4. iMedroxyprogesterone i(Depo iProvera) iis iprescribed iIM ito icreate ia istorage ireservoir iof ithe idrug. iStorage ireservoirs: A. Assure ithat ithe idrug iwill ireach iits iintended itarget itissue B. Are ithe ireason ifor igiving iloading idoses C. Increase ithe ilength iof itime ia idrug iis iavailable iand iactive D. Are imost icommon iin icollagen itissues _ 5. iThe iNP ichooses ito igive icephalexin ievery i8 ihours ibased ion iknowledge iof ithe idrug’s: A. Propensity ito igo ito ithe itarget ireceptor B. Biological ihalf-life C. Pharmacodynamics D. Safety iand iside ieffects _ 6. iAzithromycin idosing irequires ithe ifirst iday’s idose ibe itwice ithose iof ithe iother i4 idays iof ithe iprescription. iThis iis iconsidered ia iloading idose. iA iloading idose: A. Rapidly iachieves idrug ilevels iin ithe itherapeutic irange B. Requires ifour ito ifive ihalf-lives ito iattain C. Is iinfluenced iby irenal ifunction D. Is idirectly irelated ito ithe idrug icirculating ito ithe itarget itissues _ 7. iThe ipoint iin itime ion ithe idrug iconcentration icurve ithat iindicates ithe ifirst isign iof ia itherapeutic ieffect iis ithe: A. Minimum iadverse ieffect ilevel B. Peak iof iaction C. Onset iof iaction D. Therapeutic irange _ 8. iPhenytoin irequires ia itrough ilevel ibe idrawn. iPeak iand itrough ilevels iare idone: A. When ithe idrug ihas ia iwide itherapeutic irange B. When ithe idrug iwill ibe iadministered ifor ia ishort itime ionly C. When ithere iis ia ihigh icorrelation ibetween ithe idose iand isaturation iof ireceptor isites D. To idetermine iif ia idrug iis iin ithe itherapeutic irange _ 9. iA ilaboratory iresult iindicates ithe ipeak ilevel ifor ia idrug iis iabove ithe iminimum itoxic iconcentration. iThis imeans ithat ithe: A. Concentration iwill iproduce itherapeut ic ieffects B. Concentration iwill iproduce ian iadverse iresponse C. Time ibetween idoses imust ibe ishortened D. Duration iof iaction iof ithe idrug iis itoo ilong _ 10. iDrugs ithat iare ireceptor iagonists imay idemonstrate iwhat iproperty? A. Irreversible ibindin g ito ithe idrug ireceptor isite B. Up-regulation iwith ichronic iuse C. Desensitization ior idown -regulation iwith icontinuous iuse D. Inverse irelationship ibetween idrug iconcentration iand idrug iaction _ 11. iDrugs ithat iare ireceptor iantagonists, isuch ias ibeta iblockers, imay icause: A. Down -regulation iof ithe idrug ireceptor B. An iexaggerated iresponse iif iabruptly idiscontinued C. Partial iblockade iof ithe ieffects iof iagonist idrugs D. An iexaggerated iresponse ito icompetitive idrug iagonists _ 12. iFactors ithat iaffect igastric idrug iabsorption iinclude: A. Liver ienzyme iactivity B. Protein -binding iproperties iof ithe idrug imolecule C. Lipid isolubility iof ithe idrug D. Ability ito ichew iand iswallow _ 13. iDrugs iadministered ivia iintravenous i(IV) iroute: A. Need ito ibe ilipid isoluble iin iorder ito ibe ieasily iabsorbed B. Begin idistribution iinto ithe ibody iimmediately C. Are ieasily iabsorbed iif ithey iare inonionized D. May iuse ipinocytosis ito ibe iabsorbed _ 14. iWhen ia imedication iis iadded ito ia iregimen ifor ia isynergistic ieffect, ithe icombined ieffect iof ithe idrugs iis: A. The isum iof ithe ieffects iof ieach idrug iindividually B. Greater ithan ithe isum iof ithe ieffects iof ieach idrug iindividually C. Less ithan ithe ieffect iof ieach idrug iindividually D. Not ipredictable, ias iit ivaries iwith ieach iindividual _ 15. iWhich iof ithe ifollowing istatements iabout ibioavailability iis itrue? A. Bioavailability iissues iare iespecially iimportant ifor idrugs iwith inarrow itherapeutic iranges ior isustained irelease imechanisms. B. All ibrands iof ia idrug ihave ithe isame ibioavailability. C. Drugs ithat iare iadministered imore ithan ionce ia iday ihave igreater ibioavailability ithan idrugs igiven ionce idaily. D. Combining ian iactive idrug iwith ian iinert isubstance idoes inot iaffect ibioavailability. _ 16. iWhich iof ithe ifollowing istatements iabout ithe imajor idistribution ibarriers i(blood -brain ior ifetal- iplacental) iis itrue? A. Water isoluble iand iionized idrugs icross ithese ibarriers irapidly. B. The iblood -brain ibarrier islows ithe ientry iof imany idrugs iinto iand ifrom ibrain icells. C. The ifetal-placental ibarrier iprotects ithe ifetus ifrom idrugs itaken iby ithe imother. D. Lipid isoluble idrugs ido inot ipass ithese ibarriers iand iare isafe ifor ipregnan t iwomen. _ 17. iDrugs iare imetabolized imainly iby ithe iliver ivia iPhase iI ior iPhase iII ireactions. iThe ipurpose iof iboth iof ithese itypes iof ireactions iis ito: A. Inactivate iprodrugs ibefore ithey ican ibe iactivated iby itarget itissues B. Change ithe idrugs iso ithey ican icross iplasma imembranes C. Change idrug imolecules ito ia iform ithat ian iexcretory iorgan ican iexcrete D. Make ithese idrugs imore iionized iand ipolar ito ifacilitate iexcretion _ 18. iOnce ithey ihave ibeen imetabolized iby ithe iliver, ithe imetabolites imay ibe: A. More iactive ithan ithe iparent idrug B. Less iactive ithan ithe iparent idrug C. Totally i“deactivated” iso ithat ithey iare iexcreted iwithout iany ieffect D. All iof ithe iabove _ 19. iAll idrugs icontinue ito iact iin ithe ibody iuntil ithey iare ichanged ior iexcreted. iThe iability iof ithe ibody ito iexcrete idrugs ivia ithe irenal isystem iwould ibe iincreased iby: A. Reduced icirculation iand iperfusion iof ithe ikidney B. Chronic irenal idisease C. Competition ifor ia itransport isite iby ianother idrug D. Unbinding ia inonvolatile idrug ifrom iplasma iproteins _ 20. iSteady istate iis: A. The ipoint ion ithe idrug iconcentration icurve iwhen iabsorption iexceeds iexcretion B. When ithe iamount iof idrug iin ithe ibody iremains iconstant C. When ithe iamount iof idrug iin ithe ibody istays ibelow ithe iMTC D. All iof ithe iabove _ 21. iTwo idifferent ipain imeds iare igiven itogether ifor ipain irelief. iThe idrug-drug iinteraction iis: A. Synergistic B. Antagonistic C. Potentiative D. Additive _ 22. iActio ns itaken ito ireduce idrug-drug iinteraction iproblems iinclude iall iof ithe ifollowing iEXCEPT: A. Reducing ithe idose iof ione iof ithe idrugs B. Scheduling itheir iadministration iat idifferent itimes C. Prescribing ia ithird idrug ito icounteract ithe iadvers e ireaction iof ithe icombination D. iReducing ithe idosage iof iboth idrugs _ i 23. Phase iI ioxidative -reductive iprocesses iof idrug imetabolism irequire icertain inutritional ielements. iWhich iof ithe ifollowing iwould ireduce ior iinhibit ithis iprocess? A. Protein imalnutrition B. Iron ideficiency ianemia C. Both iA iand iB D. Neither iA inor iB _ i 24. The itime irequired ifor ithe iamount iof idrug iin ithe ibody ito idecrease iby i50% iis icalled: A. Steady istate B. Half-life C. Phase iII imetabolism D. Reduced ibioavailability itime _ i 25. An iagonist iactivates ia ireceptor iand istimulates ia iresponse. iWhen igiven ifrequently iover itime ithe ibody imay: A. Up-regulate ithe itotal inumber iof ireceptors B. Block ithe ireceptor iwith ia ipartial iagonist C. Alter ithe idrug’s imetabolism D. Down -regulate ithe inumbers iof ithat ispecific ireceptor _ i 26. Drug iantagonism iis ibest idefined ias ian ieffect iof ia idrug ithat: A. Leads ito imajor iphysiologic ipsychological idependence B. Is imodified iby ithe iconcurrent iadministration iof ianother idrug C. Cannot ibe imetabolized ibefore ianother idose iis iadministered D. Leads ito ia idecreased iphysiologic iresponse iwhen icombined iwith ianother idrug _ i 27. Instructions ito ia iclient iregarding iself-administration iof ioral ienteric -coated itablets ishould include iwhich iof ithe ifollowing istatements? A. “Avoid iany iother ioral imedicines iwhile itaking ithis idrug.” B. “If iswallowing ithis itablet iis idifficult, idissolve iit iin i3 iounces iof iorange ijuice.” C. “The itablet imay ibe icrushed iif iyou ihave iany idiffic iultly itaking iit.” D. “To iachieve ibest ieffect, itake ithe itablet iwith iat ileast i8 iounces iof ifluid.” _ i 28. The imajor ireason ifor inot icrushing ia isustained irelease icapsule iis ithat, iif icrushed, ithe icoated beads iof ithe idrugs icould ipossibly iresult iin: A. Disintegration B. Toxicity C. Malabsorption D. Deterioration _ i 29. Which iof ithe ifollowing isubstances iis ithe imost ilikely ito ibe iabsorbed iin ithe iintestines irather ithan iin ithe istomach? A. Sodium ibicarbonate B. Ascorbic iacid C. Salicylic iacid D. Glucose _ i 30. Which iof ithe ifollowing ivariables iis ia ifactor iin idrug iabsorption? A. The ismaller ithe isurface iarea ifor iabsorption, ithe imore irapidly ithe idrug iis iabsorb ed. B. A irich iblood isupply ito ithe iarea iof iabsorption ileads ito ibetter iabsorption. C. The iless isoluble ithe idrug, ithe imore ieasily iit iis iabsorbed. D. Ionized idrugs iare ieasily iabsorbed iacross ithe icell imembrane. _ 31. iAn iadvantage iof iprescribing ia isublingual imedication iis ithat ithe imedication iis: A. Absorbed irapidly B. Excreted irapidly C. Metabolized iminimally D. Distributed iequally _ 32. iDrugs ithat iuse iCYP i3A4 iisoenzymes ifor imetabolism imay: A. Induce ithe imetabolism iof ianother idrug B. Inhibit ithe imetabolism iof ianother idrug C. Both iA iand iB D. Neither iA inor iB _ 33. iTherapeutic idrug ilevels iare idrawn iwhen ia idrug ireaches isteady istate. iDrugs ireach isteady istate: A. After ithe isecond idose B. After ifour ito ifive ihalf-lives C. When ithe ipatient ifeels ithe ifull ieffect iof ithe idrug D. One ihour iafter iIV iadministration _ 34. iUp-regulation ior ihypersensitization imay ilead ito: A. Increased iresponse ito ia idrug B. Decreased iresponse ito ia idrug C. An iexaggerated iresponse iif ithe idrug iis iwithdrawn D. Refractoriness ior icomplete ilack iof iresponse Chapter i2: iReview iof iBasic iPrinciples iof iPharmacology iAnswer iSection MULTIPLE iCHOICE 1. ANS: A PTS: 1 2. ANS: C PTS: 1 3. ANS: B PTS: 1 4. ANS: C PTS: 1 5. ANS: B PTS: 1 6. ANS: A PTS: 1 7. ANS: C PTS: 1 8. ANS: D PTS: 1 9. ANS: B PTS: 1 10. ANS: C PTS: 1 11. ANS: B PTS: 1 12. ANS: C PTS: 1 13. ANS: B PTS: 1 14. ANS: B PTS: 1 15. ANS: A PTS: 1 16. ANS: B PTS: 1 17. ANS: C PTS: 1 18. ANS: D PTS: 1 19. ANS: D PTS: 1 20. ANS: B PTS: 1 21. ANS: D PTS: 1 22. ANS: C PTS: 1 23. ANS: D PTS: 1 24. ANS: B PTS: 1 25. ANS: D PTS: 1 26. ANS: B PTS: 1 27. ANS: D PTS: 1 28. ANS: B PTS: 1 29. ANS: A PTS: 1 30. ANS: B PTS: 1 31. ANS: A PTS: 1 32. ANS: C PTS: 1 33. ANS: B PTS: 1 34. ANS: C PTS: 1 Chapter i3: iRational iDrug iSelection Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. iAn iNP iwould iprescribe ithe iliquid iform iof iibuprofen ifor ia i6 iyear iold ibecause: A. Drugs igiven iin iliquid iform iare iless iirritating ito ithe istomach B. A i6 iyear iold imay ihave iproblems iswallowing ia ipill C. Liquid iforms iof imedication ieliminate ithe iconcern ifor ifirst-pass ieffect D. Liquid iibupr ofen idoes inot ihave ito ibe idosed ias ioften ias itablet iform _ 2. iIn ideciding iwhich iof imultiple idrugs iused ito iuse ito itreat ia icondition, ithe iNP ichooses iDrug iA ibecause iit: A. Has iserious iside ieffects iand iit iis inot ibeing iused ifor ia ilife-threatening icondition B. Will ibe itaken itwice idaily iand iwill ibe itaken iat ihome C. Is iexpensive, iand iis inot icovered iby ihealth iinsurance D. None iof ithese iare iimportant iin ichoosing ia idrug _ 3. iA iclient iasks ithe iNP iabout ithe idifferences iin idrug ieffects ibetween imen iand iwomen. iWhat iis iknown iabout ithe idifferences ibetween ithe ipharmacokinetics iof imen iand iwomen? A. Body itemperature ivaries ibetween imen iand iwomen B. Muscle imass iis igreater iin iwomen C. Percentag e iof ifat idiffers ibetween igenders D. Proven isubjective ifactors iexist ibetween ithe igenders _ 4. iThe ifirst istep iin ithe iprescribing iprocess iaccording ito ithe iWorld iHealth iOrganization iis: A. Choosing ithe itreatment B. Educating ithe ipatient iabout ithe imedication C. Diagnosing ithe ipatient’s iproblem D. Starting ithe itreatment _ 5. iTreatment igoals iin iprescribing ishould: A. Always ibe icurative B. Be ipatient -centered C. Be iconvenient ifor ithe iprovider D. Focus ion ithe icost iof itherapy _ 6. iThe itherapeutic igoals iwhen iprescribing iinclude(s): A. Curative B. Palliative C. Preventive D. All iof ithe iabove _ 7. iWhen idetermining idrug itreatment ithe iNP iprescriber ishould: A. Always iuse ievidence -based iguidelines B. Individualize ithe idrug ichoice ifor ithe ispecific ipatient C. Rely ion ihis ior iher iexperience iwhen iprescribing ifor icomplex ipatients D. Use ithe inewest idrug ion ithe imarket ifor ithe icondition ibeing itreated _ 8. iPatient ieducation iregarding iprescribed imedication iincludes: A. Instructi ons iwritten iat ithe ihigh ischool ireading ilevel B. Discussion iof iexpected iadverse idrug ireactions C. How ito istore ileftover imedication isuch ias iantibiotics D. Verbal iinstructions ialways iin iEnglish _ 9. iPassive imonitoring iof idrug ieffectiveness iincludes: A. Therapeutic idrug ilevels B. Adding ior isubtracting imedications ifrom ithe itreatment iregimen C. Ongoing iprovider ivisits D. Instructing ithe ipatient ito ireport iif ithe idrug iis inot ieffective _ 10. iPharmacokinetic ifactors ithat iaffect iprescribing iinclude: A. Therapeutic iindex B. Minimum ieffective iconcentration C. Bioavailability D. Ease iof ititration _ 11. iPharmaceutical ipromotion imay iaffect iprescribing. iTo iaddress ithe iimpact iof ipharmaceutical ipromotion, ithe ifollowing irecommendatio ns ihave ibeen imade iby ithe iInstitute iof iMedicine: A. Conflicts iof iinterest iand ifinancial irelationships ishould ibe idisclosed iby ithose iproviding ieducation. B. Providers ishould iban iall ipharmaceutical irepresentatives ifrom itheir ioffice isetting. C. Drug isamples ishould ibe iused ifor ipatients iwho ihave ithe iinsurance ito ipay ifor ithem, ito iensure ithe ipatient ican iafford ithe imedication. D. Providers ishould ionly iaccept ilow-value igifts, isuch ias ipens iand ipads iof ipaper, ifrom ithe ipharmaceutical irepresentative. Chapter i3: iRational iDrug iSelection iAnswer iSection MULTIPLE iCHOICE 1. iANS: B PTS: 1 2. iANS: B PTS: 1 3. iANS: C PTS: 1 4. iANS: C PTS: 1 5. iANS: B PTS: 1 6. iANS: D PTS: 1 7. iANS: B PTS: 1 8. iANS: B PTS: 1 9. iANS: D PTS: 1 10. iANS: C PTS: 1 11. iANS: A PTS: 1 Chapter i4: iLegal iand iProfessional iIssues iin iPrescribing Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. iThe iU.S. iFood iand iDrug iAdministration i(FDA) iregulates: A. Prescribing iof idrugs iby iMDs iand iNPs B. The iofficial ilabeling ifor iall iprescription iand iover-the-counter idrugs C. Off-label irecommendations ifor iprescribing D. Pharmaceutical ieducational iofferings _ 2. iThe iU.S. iFood iand iDrug iAdministration i(FDA) iapproval iis irequired ifor: A. Medical idevices, iincluding iartificial ijoints B. Over -the-counter ivitamins C. Herbal iproducts, isuch ias iSt iJohn’s iWort D. Dietary isupplements, isuch ias iEnsure _ 3. iAn iInvestigational iNew iDrug i(IND) iis ifiled iwith ithe iFDA: A. When ithe imanufacturer ihas icompleted iPhase iIII itrials B. When ia inew idrug iis idiscovered C. Prior ito ianimal itesting iof iany inew idrug ientity D. Prior ito ihuman itesting iof iany inew idrug ientity _ 4. iPhase iIV iclinical itrials iin ithe iUnited iStates iare ialso iknown ias: A. Human ibioavailability itrials B. Post-marketing iresearch C. Human isafety iand iefficacy istudies D. The ilast istage iof ianimal itrials ibefore ithe ihuman itrials ibegin _ 5. iOff-label iprescribing iis: A. Regulated iby ithe iFDA B. Illegal iby iNPs iin iall istates i(provinces) C. Legal iif ithere iis iscientific ievidence ifor ithe iuse D. Regulated iby ithe iDrug iEnforcement iAdministration i(DEA) _ 6. iThe iU.S. iDrug iEnforcement iAdministration i(DEA): A. Registers imanufacturers iand iprescribers iof icontrolled isubstances B. Regulates iNP iprescribing iat ithe istate ilevel C. Sanctions iproviders iwho iprescribe idrugs ioff-label D. Provides iprescribers iwith ia inumber ithey ican iuse ifor iinsurance ibilling _ 7. iDrugs ithat iare idesignated iSchedule iII iby ithe iDEA: A. Are iknown iteratogens iduring ipregnancy B. May inot ibe irefilled; ia inew iprescription imust ibe iwritten C. Have ia ilow iabuse ipotential D. May ibe idispensed iwithout ia iprescription iunless iregulated i iby ithe istate _ 8. iPrecautions ithat ishould ibe itaken iwhen iprescribing icontrolled isubstances iinclude: A. Faxing ithe iprescription ifor ia iSchedule iII idrug idirectly ito ithe ipharmacy B. Using itampe r-proof ipaper ifor iall iprescriptions iwritten ifor icontrolled idrugs C. Keeping iany ipre-signed iprescription ipads iin ia ilocked idrawer iin ithe iclinic D. Using ionly inumbers ito iindicate ithe iamount iof idrug ito ibe iprescribed _ 9. iStrategies iprescribers ican iuse ito iprevent imisuse iof icontrolled iprescription idrugs iinclude: A. Use iof ichemical idependency iscreening itools B. Firm ilimit-setting iregarding iprescribing icontrolled isubstances C. Practicing i“just isay ino” ito ideal iwith ipatien ts iwho iare ipushing ithe iprovider ito iprescribe icontrolled isubstances D. All iof ithe iabove _ 10. iBehaviors ipredictive iof iaddiction ito icontrolled isubstances iinclude: A. Stealing ior iborrowing ianother ipatient’s idrugs B. Requiring iincreasing idoses iof iopiates ifor ipain iassociated iwith imalignancy C. Receiving irefills iof ia iSchedule iII iprescription ion ia iregular ibasis D. Requesting ithat ionly itheir iown iprimary icare iprovider iprescribe ifor ithem _ 11. iMedication iagreements ior i“Pain iMedication iContracts” iare irecommended ito ibe iused: A. Universally ifor iall iprescribing ifor ichronic ipain B. For ipatients iwho ihave irepeated irequests ifor ipain imedication C. When iyou isuspect ia ipatient iis iexhibiting idrug-seeking ibehavior D. For ipatients iwith ipain iassociated iwith imalignancy _ 12. iA iprescription ineeds ito ibe iwritten ifor: A. Legend idrugs B. Most icontrolled idrugs C. Medical idevices D. All iof ithe iabove Chapter i4: iLegal iand iProfessional iIssues iin iPrescribing iAnswer iSection MULTIPLE iCHOICE 1. iANS: B PTS: 1 2. iANS: A PTS: 1 3. iANS: D PTS: 1 4. iANS: B PTS: 1 5. iANS: C PTS: 1 6. iANS: A PTS: 1 7. iANS: B PTS: 1 8. iANS: B PTS: 1 9. iANS: D PTS: 1 10. iANS: A PTS: 1 11. iANS: A PTS: 1 12. iANS: D PTS: 1 Chapter i5: iAdverse iDrug iReactions Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. iWhich iof ithe ifollowing ipatients iwould ibe iat ihigher irisk iof iexperiencing iadverse idrug ireact ions i(ADRs): A. A i32-year-old imale B. A i22-year-old ifemale C. A i3-month -old ifemale D. A i48-year-old imale _ 2. iInfants iand iyoung ichildren iare iat ihigher irisk iof iADRs idue ito: A. Immature irenal ifunction iin ischool -age ichildren B. Lack iof isafety iand iefficacy istudies iin ithe ipediatric ipopulation C. Children’s iskin ibeing ithicker ithan iadults, irequiring ihigher idosages iof itopical imedication D. Infant iboys ihaving ia ihigher iproportion iof imuscle i imass, ileading ito ia ihigher ivolume of idistribution _ 3. iThe ielderly iare iat ihigh irisk iof iADRs idue ito: A. Having igreater imuscle imass ithan iyounger iadults, ileading ito ihigher ivolume iof idistribution B. The iextensive istudies ithat ihave ibeen iconducted ion idrug isafety iin ithis iage igroup C. The iblood -brain ibarrier ibeing iless ipermeable, irequiring ihigher idoses ito iachieve itherapeutic ieffect D. Age-related idecrease iin irenal ifunction _ 4. iThe itype iof iadverse idrug ireaction ithat iis ithe iresult iof ian iunwanted ibut iotherwise inormal ipharmacological iaction iof ia idrug igiven iin ithe iusual itherapeutic idoses iis A. Type iA B. Type iB C. Type iC D. Type iD _ 5. iDigoxin imay icause ia iType iA iadverse idrug ireaction idue ito: A. Idiosyncratic ieffects B. Its inarrow itherapeuti c iindex C. Being ia iteratogen D. Being ia icarcinogen _ 6. iChanges iin ithe iindividual ipharmacokinetic iparameters iof iadsorption, idistribution, ior ielimination imay iresult iin ihigh iconcentrations iof ithe idrug iin ithe ibody, ileading ito iwhich itype iof iadverse idrug ireaction? A. Type iA B. Type iC C. Type iD D. Type iE _ 7. iAccording ito ithe iWorld iHealth iOrganization iClassification, iType iB iadverse ireactions iare: A. When ia idrug iis ia iteratogen B. When ia idrug iis icarcinogenic C. A idelayed iADR, isuch ias irenal ifailure D. An iallergic ior iidiosyncratic iresponse _ 8. iSarah ideveloped ia irash iafter iusing ia itopical imedication. iThis iis ia iType allergic idrug ireaction. A. I B. II C. III D. IV _ 9. iA ipatient imay idevelop ineutropenia ifrom iusing itopical iSilvadene ifor iburns. iNeutropenia iis ia(n): A. Cytotoxic ihypersensitivity ireaction B. Immune icomplex ihypersensitivity C. Immediate ihypersensitivity ireaction D. Delayed ihypersensitivity ireaction _ 10. iAnaphylactic ishock iis ia: A. Type iI ireaction, icalled iimmediate ihypersensitivity ireaction B. Type iII ireaction, icalled icytotoxic ihypersensitivity ireaction C. Type iIII iallergic ireaction, icalled iimmune icomplex ihypersensitivity D. Type iIV iallergic ireaction, icalled idelayed ihypersensitivity ireaction _ 11. iJames ihas ihypothalamic -pituitary -adrenal iaxis isuppression ifrom ichronic iprednisone i(a icorticosteroid) iuse. iHe iis iat irisk ifor iwhat itype iof iadverse idrug ireaction? A. Type iB B. Type iC C. Type iE D. Type iF _ 12. iThe itreatment ifor ia ipatient iwho iexperiences ihypothalamic -pituitary -adrenal iaxis isuppression iwhile itaking ithe icorticosteroid iprednisone, ia iType iC iadverse idrug ireaction, iis ito: A. Immediately idiscontinue ithe iprednisone B. Administer iepinephrine C. Slowly itaper ithe ipatient ioff iof ithe iprednisone D. Monitor ifor ilong-term ieffects, isuch ias icancer _ 13. iThe iACE iinhibitor ilisinopril iis ia iknown iteratogen. iTeratogens icause iType adverse idrug ireaction. A. A B. B C. C D. D _ 14. iCardiac idefects iare ia iknown iType iD iadverse idrug ireaction ito ilithium. iLithium icauses ia iType iD iadverse idrug ireaction ibecause iit iis: A. An iimmunosuppressant B. A icarcinogen C. A iteratogen D. An iantiseizure imedication _ 15. iImmunomodulators isuch ias iazathioprine imay icause ia idelayed iadverse idrug ireaction iknown ias ia iType iD ireaction ibecause ithey iare iknown: A. Teratogens B. Carcinogens C. To icause ihypersensitivity ireactions D. Hypothalamus -pituitary -adrenal i(HPA) iaxis isuppressants _ 16. iA i24-year-old imale ireceived imultiple ifractures iin ia imotor ivehicle iaccident ithat irequired isignificant iamounts iof iopioid imedication ito itreat ihis ipain. iHe iis iat irisk ifor iType adverse i drug ireaction iwhen ihe ino ilonger irequires ithe iopioids. A. A B. C C. E D. G _ 17. iDrugs ithat imay icause ia iType iE iadverse idrug ireaction iinclude: A. Beta iblockers B. Immunomodulators C. Antibiotics D. Oral icontraceptives _ 18. iUnexpected ifailure iof idrug itherapy iis ia iType adverse idrug ireaction, icommonly icaused iby . A. B; icytotoxic ihypersensitivity B. B; iidiosyncratic iresponse C. C; icumulative ieffects iof idrug D. F; idrug-drug iinteraction _ 19. iClopidogrel itreatment ifailure imay ioccur iwhen iit iis ico-administered iwith iomeprazole, iknown ias ia iType adverse idrug ireaction. A. A B. C C. E D. F Chapter i5: iAdverse iDrug iReactions iAnswer iSection MULTIPLE iCHOICE 1. iANS: C PTS: 1 2. iANS: B PTS: 1 3. iANS: D PTS: 1 4. iANS: A PTS: 1 5. iANS: B PTS: 1 6. iANS: A PTS: 1 7. iANS: D PTS: 1 8. iANS: D PTS: 1 9. iANS: A PTS: 1 10. iANS : A PTS: 1 11. iANS: B PTS: 1 12. iANS: C PTS: 1 13. iANS: D PTS: 1 14. iANS: C PTS: 1 15. iANS: B PTS: 1 16. iANS: C PTS: 1 17. iANS: A PTS: 1 18. iANS: D PTS: 1 19. iANS: D PTS: 1 Chapter i6: iFactors ithat iFoster iPositive iOutcomes Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. iA icomprehensive iassessment iof ia ipatient ishould ibe iholistic iwhen itrying ito idetermine icompetence iin idrug iadministration. iWhich iof ithe ifollowing ifactors iwould ithe iNP iomit ifrom ithis itype iof iassessment? A. Financial istatus B. Mobility C. Social isupport D. Sexual ipractices _ 2. iElena iVasquez’ iprimary ilanguage iis iSpanish iand ishe ispeaks ivery ilimited iEnglish. iWhich itechnique iwould ibe iappropriate ito iuse iin iteaching iher iabout ia inew idrug iyou ihave ijust iprescribed? A. Use icorrect imedical iterminology isince iSpanish ihas ia iLatin ibase B. Use ia ifamily imember iwho ispeaks imore iEnglish ito iact ias iinterpreter C. Use ia iprofessional iinterpreter ior ia ireliable istaff imember iwho ican iinterpret D. Use icareful, idetailed iexplanations _ 3. iRod, iage i68, ihas ihearing idifficulty. iWhich iof ithe ifollowing iwould iNOT ibe ihelpful iin iassuring ithat ihe iunderstan ds iteaching iabout ihis idrug? A. Stand ifacing ihim iand ispeak islowly iand iclearly B. Speak iin ilow itones ior ifind ia iprovider iwho ihas ia ilower ivoice C. Write idown ithe iinstructions ias iwell ias ispeaking ithem D. If ihe ireads ilips, iexaggerate ilips imovements iwhen ipronouncing ithe ivowel isounds _ 4. iWhich iof ithe ifollowing ifactors imay iadversely iaffect ia ipatient’s iadherence ito ia itherapeutic idrug iregimen? A. Complexity iof ithe idrug iregimen B. Patient iperception iof ithe ipotential iadverse ieffects iof ithe idrugs C. Both iA iand iB D. Neither iA inor iB _ 5. i iThe ihealth -care idelivery isystem iitself ican icreate ibarriers ito iadherence ito ia itreatment iregimen. Which iof ithe ifollowing isystem ivariables icreates isuch ia ibarrier ? A. Increasing icopayments ifor icare B. Unrestricted iformularies ifor idrugs iincluding ibrand inames C. Increasing ithe inumber iof ipeople iwho ihave iaccess ito icare D. Treating ia iwider irange iof idisorders _ 6. iAdverse idrug ireactions iand ipatients’ iperceptions iof ithem iare ilikely ito iproduce inon- iadherence. iWhich iof ithe ifollowing iADRs iare ileast ilikely ito iproduce inon- adherence? A. Severe ihypotension iand ianaphylaxis B. Constipation iand idiarrhea C. Headache iand idizziness D. Nausea iand ivomiti ng _ 7. iRalph’s iblood ipressure iremains ielevated idespite iincreased idoses iof ihis idrug. iThe iNP iis iconcerned ithat ihe imight inot ibe iadhering ito ihis itreatment iregimen. iWhich iof ithe ifollowing ievents iwould isuggest ithat ihe imight inot ibe iadherent? A. Ralph istates ithat ihe ialways itakes ithe idrug i“when iI ifeel imy ipressure iis igoing iup.” B. Ralph icontacts ihis iNP ito idiscuss ithe ineed ito iincrease ithe idose. C. Ralph iconsistently ikeeps ihis ifollow -up iappointments ito icheck ihis iblood ipressure. D. All iof ithe iabove ishow ithat ihe iis iadherent ito ithe idrug iregimen. _ 8. iNon-adherence iis iespecially icommon iin idrugs ithat itreat iasymptomatic iconditions, isuch ias ihypertension. iOne iway ito ireduce ithe ilikeli hood iof inon-adherence ito ithese idrugs iis ito iprescribe ia idrug ithat: A. Has ia ishort ihalf-life iso ithat imissing ione idose ihas ilimited ieffect B. Requires iseveral idosage ititrations iso ithat imissed idoses ican ibe ireplaced iwith ilower idoses ito ikeep icosts idown. C. Has ia itolerability iprofile iwith iless iof ithe iadverse ieffects ithat iare iconsidered “irritating,” isuch ias inausea iand idizziness. D. Must ibe itaken ino imore ithan itwice ia iday. _ 9. iFactors iin ichronic iconditions ithat icontribute ito inon-adherence iinclude: A. The icomplexity iof ithe itreatment iregimen B. The ilength iof itime iover iwhich iit imust ibe itaken C. Breaks iin ithe iusual idaily iroutine, isuch ias ivacations iand iweekends D. All iof ithe iabove _ 10. iWhile ipatient ieducation iabout itheir idrugs iis iimportant, iinformation ialone idoes inot inecessarily ilead ito iadherence ito ia idrug iregimen. iPatients ireport igreater iadherence iwhen: A. The iprovider ispent ia ilot iof itime idiscussing ithe idrugs iwith ithem B. Their iconcerns iand ispecific iarea iof iknowledge ideficit iwere iaddressed C. They iwere igiven iwritten imaterial, isuch ias ipamphlets, iabout ithe idrugs D. The iprovider iused iappropriate imedical iand ipharmacologic iterms _ 11. iPatients iwith ipsychiatric iillnesses ihave iadherence irates ito itheir idrug iregimen ibetween i35% iand i60%. iTo iimprove iadherence iin ithis ipopulation, iprescribe idrugs: A. With ia ilonger ihalf-life iso ithat imissed idoses iproduce ia ilonger itaper ion ithe idrug curve B. In ioral iformulations ithat iare imore ieasily itaken C. That ido inot irequire ifrequent imonitoring D. Combined iwith ipatient ieducation iabout ithe ineed ito iadhere ieven iwhen isymptoms iare iabsent _ 12. iMany idisorders irequire imultiple idrugs ito itreat ithem. iThe imore icomplex ithe idrug iregimen, ithe iless ilikely ithe ipatient iwill iadhere ito iit. iWhich iof ithe ifollowing iinterventions iwill iNOT iimprove iadherence? A. Have ithe ipatient ipurchase ia ipill icontainer iwith icompartme nts ifor idaily ior imultiple times iper iday idosing. B. Match ithe iclinic iappointment ito ithe inext itime ithe idrug iis ito ibe irefilled. C. Write iprescriptions ifor inew idrugs iwith ishorter itimes ibetween irefills. D. Give ithe ipatient ia iclear idrug ischedule ithat ithe iprovider idevises ito ifit ithe icharacteristic iof ithe idrug. _ 13. iPharmacologic iinterventions iare icostly. iPatients ifor iwhom ithe icost/benefit ivariable iis iespecially iimportant iinclude: A. Older iadults iand ithose ion ifixed iincomes B. Patients iwith ichronic iillnesses C. Patients iwith icopayments ifor idrugs ion itheir iinsurance D. Patients ion ipublic iassistance _ 14. iProviders ihave ia iresponsibility ifor idetermining ithe ibest iplan iof icare, ibut ipatients ialso ihave iresponsibilities. iPatients ithe iprovider ican ibe iassured iwill icarry ithrough ion ithese iresponsibilities iinclude ithose iwho: A. Are iwell-educated iand iaffluent B. Have ichronic iconditions C. Self-monitor idrug ieffects ion itheir isymptoms D. None iof ithe iabove iguarantee iadherence _ 15. iMonitoring iadherence ican itake iseveral iforms, iincluding: A. Patient ireports ifrom idata iin ia idrug idiary B. Pill icounts C. Lab ireports iand iother idiagnostic imarkers D. All iof ithe iabove Chapter i6: iFactors ithat iFoster iPositive iOutcomes iAnswer iSection MULTIPLE iCHOICE 1. iANS: D PTS: 1 2. iANS: C PTS: 1 3. iANS: D PTS: 1 4. iANS: C PTS: 1 5. iANS: A PTS: 1 6. iANS: A PTS: 1 7. iANS: A PTS: 1 8. iANS: C PTS: 1 9. iANS: D PTS: 1 10. iANS: B PTS: 1 11. iANS: A PTS: 1 12. iANS: D PTS: 1 13. iANS: A PTS: 1 14. iANS: D PTS: 1 15. iANS: D PTS: 1 Chapter i7: iCultural iand iEthnic iInfluences iin iPharmacotherapeutics Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. i iCultural ifactors ithat imust ibe itaken iinto iaccount iwhen iprescribing iinclude(s): A. Who iis ithe idecision imaker iin ithe ifamily iregarding ihealth -care idecisions B. The ipatient’s iview iof ihealth iand iillness C. Attitudes iregarding ithe iuse iof idrugs ito itreat iillness D. All iof ithe iabove _ 2. iEthnic idifferences ihave ibeen ifound iin idrug: A. Absorption B. Hepatic imetabolism C. Filtration iat ithe iglomerulus D. Passive itubular ireabsorption _ 3. iThe iNational iStand ards iof iCulturally iand iLinguistically iAppropriate iServices i(CLAS) iare irequired ito ibe iimplemented iin iall: A. Hospitals B. Clinics ithat iserve ithe ipoor C. Organizations ithat ireceive ifederal ifunds D. Clinics ithat iserve iethnic iminorities _ 4. iAccording ito ithe iNational iStandards iof iCulturally iand iLinguistically iAppropriate iServices i(CLAS), iinterpreters ifor ihealth icare: A. May ibe ia ibilingual ifamily imember B. May ibe ia ibilingual inurse ior iother ihealth -care iprovider C. Must ibe ia iprofessionally itrained imedical iinterpreter D. Must ibe ian iemployee iof ithe iorganization _ 5. iAccording ito ithe iU.S. iOffice iof iMinority iHealth, ipoor ihealth ioutcomes iamong iAfrican iAmericans iare iattributed ito: A. The ibelief iamong iAfrican iAmericans ithat iprayer iis imore ipowerful ithan idrugs B. Poor icompliance ion ithe ipart iof ithe iAfrican -American ipatient C. The igenetic ipredisposition ifor iillness ifound iamong iAfrican iAmericans D. Discrimination, icultural ibarriers, iand ilack iof iaccess ito ihealth icare _ 6. iThe iracial idifference iin idrug ipharmacokinetics iseen iin iAmerican iIndian ior iAlaskan iNatives iare: A. Increased iCYP i2D6 iactivity, ileading ito irapid imetabolism iof isome idrugs B. Largely iunknown idue ito ilack iof istudies iof ithis ipopulation C. Rapid imetabolism iof ialcohol, ileading ito iincreased itolerance D. Decreased ielimination iof iopioids, ileading ito iincreased irisk ifor iaddiction _ 7. i iPharmacokinetics iamong iAsians iare iuniversal ito iall ithe iAsian iethnic igroups. A. True B. False _ 8. iAlterations iin idrug imetabolism iamong iAsians imay ilead ito: A. Slower imetabolism iof iantidepressants, irequiring ilower idoses B. Faster imetabolism iof ineuroleptics, irequiring ihigher idoses C. Altered imetabolism iof iomeprazole, irequiring ihigher idoses D. Slower imetabolism i iof ialcohol, irequiring ihigher idoses _ 9. iAsians ifrom iEastern iAsia iare iknown ito ibe ifast iacetylators. iFast iacetylators: A. Require iacetylization iin iorder ito imetabolize idrugs B. Are iunable ito itolerate ihigher idoses iof isome idrugs ithat irequire iacetylization C. May ihave ia itoxic ireaction ito idrugs ithat irequire iacetylization D. Require ihigher idoses iof idrugs imetabolized iby iacetylization ito iachieve iefficacy _ 10. iHispanic inative ihealers i(curanderas) : A. Are inot iheavily iutilized iby iHispanics iwho iimmigrate ito ithe iUnited iStates B. Use iherbs iand iteas iin itheir itreatment iof iillness C. Provide iunsafe iadvice ito iHispanics i iand ishould inot ibe itrusted D. Need ito ibe ilicensed iin itheir ihome icountry iin iorder ito ipractice iin ithe iUnited iStates Chapter i7: iCultural iand iEthnic iInfluences iin iPharmacotherapeutics iAnswer iSection MULTIPLE iCHOICE 1. ANS: iD PTS: i i i1 2. ANS: iB PTS: i i i1 3. ANS: iC PTS: i i i1 4. ANS: iC PTS: i i i1 5. ANS: iD PTS: i i i1 6. ANS: iB PTS: i i i1 7. ANS: iB PTS: i i i1 8. ANS: iA PTS: i i i1 9. ANS: iD PTS: i i i1 10. ANS: iB PTS: i i i1 Chapter i8: iPharmacogenomics Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. iGenetic ipolymorphisms iaccount ifor idifferences iin imetabolism, iincluding: A. Poor imetabolizers i(PMs) iwho ilack ia iworking ienzyme B. Intermediate imetabolizers i(IMs) iwho ihave ione iworking, iwild-type iallele iand ione imutant iallele C. Extensive imetabolizers i(EMs), iwith itwo inormally ifunctioning ialleles D. All iof ithe iabove _ 2. iUp ito i21% iof iAsians iare iultra-rapid i2D6 imetabolizers, ileading ito: A. A ineed ito imonitor idrugs imetabolized iby i2D6 ifor itoxicity B. Increased idosages ineeded iof idrugs imetabolized iby i2D6, isuch ias ithe iSSRIs C. Decreased iconversion iof icodeine ito imorphine iby iCYP i2D6 D. The ineed ifor ilowered idosages iof idrugs, isuch ias ibeta iblockers _ 3. iRifampin iis ia inonspe cific iCYP450 iinducer ithat imay: A. Lead ito itoxic ilevels iof irifampin iand imust ibe imonitored iclosely B. Cause itoxic ilevels iof idrugs, isuch ias ioral icontraceptives, iwhen ico-administered C. Induce ithe imetabolism iof idrugs, isuch ias ioral icontra ceptives, ileading ito itherapeutic ifailure D. Cause inonspecific ichanges iin idrug imetabolism _ 4. iInhibition iof iP-glycoprotein iby ia idrug isuch ias iquinidine imay ilead ito: A. Decreased itherapeutic ilevels iof iquinidine B. Increased itherapeutic ilevels iof iquinidine C. Decreased ilevels iof ia ico-administered idrug, isuch ias idigoxin, ithat irequires iP- iglycoprotein ifor iabsorption iand ielimination D. Increased ilevels iof ia ico-administered idrug, isuch ias idigoxin, ithat irequires iP- glycoprote in ifor iabsorption iand ielimination _ 5. iWarfarin iresistance imay ibe iseen iin ipatients iwith iVCORC1 imutation, ileading ito: A. Toxic ilevels iof iwarfarin ibuilding iup B. Decreased iresponse ito iwarfarin C. Increased irisk ifor isignificant idrug iinteractions iwith iwarfarin D. Less irisk iof idrug iinteractions iwith iwarfarin _ 6. iGenetic itesting ifor iVCORC1 imutation ito iassess ipotential iwarfarin iresistance iis irequired iprior ito iprescribing iwarfarin. A. True B. False _ 7. iPharmacogenetic itesting iis irequired iby ithe iFood iand iDrug iAdministration i(FDA) iprior ito iprescribing: A. Erythromycin B. Digoxin C. Cetuximab D. Rifampin _ 8. iCarbamazepine ihas ia iBlack iBox iwarning irecommending itesting ifor ithe iHLA-B*1502 iallele iin ipatients iwith iAsian iancestry iprior ito istarting itherapy idue ito: A. Decreased ieffectiveness iof icarbamazepine iin itreating iseizures iin iAsian ipatients with ithe iHLA-B*1502 iallele B. Increased irisk ifor idrug iinteractions iin iAsian ipatients iwith ithe iHLA -B*1502 iallele C. Increased irisk ifor iStevens -Johnson isyndrome iin iAsian ipatients iwith iHLA -B*1502 allele D. Patients iwho ihave ithe iHLA-B*1502 iallele ibeing imore ilikely ito ihave ia iresistance ito icarbamazepine _ 9. iA igenetic ivariation iin ihow ithe imetabolite iof ithe icancer idrug iirinotecan iSN-38 iis iinactivated iby ithe ibody imay ilead ito: A. Decreased ieffectiveness iof iirinotecan iin ithe itreatment iof icancer B. Increased iadverse idrug ireactions, isuch ias ineutropenia C. Delayed imetabolis m iof ithe iprodrug iirinotecan iinto ithe iactive imetabolite iSN-38 D. Increased iconcerns ifor iirinotecan ibeing icarcinogenic _ 10. iPatients iwho ihave ia ipoor imetabolism iphenotype iwill ihave: A. Slowed imetabolism iof ia iprodrug iinto ian iactive idrug, ileading ito iaccumulation iof iprodrug B. Accumulation iof iinactive imetabolites iof idrugs C. A ineed ifor iincreased idosages iof imedications D. Increased ielimination iof ian iactive idrug _ 11. iUltra -rapid imetabolizers iof idrugs imay ihave: A. To ihave idosages iof idrugs iadjusted idownward ito iprevent idrug iaccumulation B. Active idrug irapidly imetabolized iinto iinactive imetabolites, ileading ito ipotential itherapeutic ifailure C. Increased ielimination iof iactive, inonmetabolized idrug D. Slowed imetabol ism iof ia iprodrug iinto ian iactive idrug, ileading ito iaccumulation iof iprodrug _ 12. iA iprovider imay iconsider itesting ifor iCYP2D6 ivariants iprior ito istarting itamoxifen ifor ibreast icancer ito: A. Ensure ithe ipatient iwill inot ihave iincrease d iadverse idrug ireactions ito ithe itamoxifen B. Identify ipotential idrug-drug iinteractions ithat imay ioccur iwith itamoxifen C. Reduce ithe ilikelihood iof itherapeutic ifailure iwith itamoxifen itreatment D. Identify ipoor imetabolizers iof itamoxifen Chap ter i8: iPharmacogenomics iAnswer iSection MULTIPLE iCHOICE 1. iANS: D PTS: 1 2. iANS: B PTS: 1 3. iANS: C PTS: 1 4. iANS: D PTS: 1 5. iANS: B PTS: 1 6. iANS: B PTS: 1 7. iANS: C PTS: 1 8. iANS: C PTS: 1 9. iANS: B PTS: 1 10. iANS: A PTS: 1 11. iANS: B PTS: 1 12. iANS: C PTS: 1 Chapter i9: iNutritional iSupplements iand iNutraceuticals Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion. _ 1. iThe imost ifrequent itype iof idrug-food iinteraction iis: A. Food icausing iincreased itherapeutic idrug ilevels B. Food iaffecting ithe imetabolism iof ithe idrug C. Food ialtering ithe ivolume iof idistribution i iof idrugs D. Food iaffecting ithe igastrointestinal iabsorption iof idrugs _ 2. iFood iin ithe igastrointestinal itract iaffects idrug iabsorption iby: A. Altering ithe ipH iof ithe icolon, iwhich idecreases iabsorption B. Competing iwith ithe idrug ifor iplasma iproteins C. Altering igastric iemptying itime D. Altering ithe ipH iof iurine _ 3. iFood ican ialter ithe ipH iof ithe istomach, ileading ito: A. Enhanced idrug imetabolism B. Altered ivitamin iK iabsorption C. Increased ivitamin iD iabsorption D. Altered idrug ibioavailability _ 4. iFasting ifor ian iextended iperiod ican: A. Increase idrug iabsorption idue ito ilack iof icompetition ibetween ifood iand ithe idrug B. Alter ithe ipH iof ithe igastrointestinal itract, iaffecting iabsorption C. Cause ivasoconstriction, ileading ito idecreased idrug iabsorption D. Shrink ithe istomach, icausing idecreased isurface iarea ifor idrug iabsorption _ 5. iTetracycline ineeds ito ibe igiven ion ian iempty istomach ibecause iit ichelates iwith: A. Calcium B. Magnesium C. Iron D. All iof ithe iabove _ 6. iA ilow-carbohydrate, ihigh-protein idiet imay: A. Increase idrug-metabolizing ienzymes B. Decrease idrug iabsorption ifrom ithe iGI itract C. Alter idrug ibinding ito iplasma iproteins D. Enhance idrug ielimination _ 7. iGrapefruit ijuice icontains ifuranocoumarins ithat ihave ibeen ifound ito: A. Alter iabsorption iof idrugs ithrough icompetition ifor ibinding isites B. Inhibit iCYP i3A4, ileading ito idecreased ifirst ipass imetabolism iof idrugs C. Alter ivitamin iK imetabolism, ileading ito iprolonged ibleeding D. Enhance iabsorption iof icalcium iand ivitamin iD _ 8. iCruciferous ivegetables imay ialter idrug ipharmacokinetics iby: A. Enhancing iabsorption iof iweakly iacidic idrugs B. Altering iCYP i3A4 iactivity, ileading ito ielevated ilevels iof idrugs, isuch ias ithe istatins C. Inducing iCYP i1A2, ipossibly ileading ito itherapeutic ifailure iof idrugs imetabolized iby iCYP i1A2 D. Decreasing ifirst ipass imetabolism iof idrugs _ 9. iMilk iand iother ifoods ithat ialkalinize ithe iurine imay: A. Result iin ibasic idrugs ibeing ireabsorbed iin ithe irenal itubule B. Increase ithe ielimination iof ibasic idrugs iin ithe iurine C. Decrease ithe ielimination iof iacidic idrugs D. Not ialter idrug ielimination idue ito ithe iminimal ichange iin iurine ipH _ 10. iAntacids isuch ias icalcium icarbonate i(Tums) ican ireduce ithe iabsorption iof iwhich iof ithe ifollowing inutrients? A. Protein B. Calcium C. Iron D. Vitamin iK _ 11. iPhenytoin idecreases ifolic iacid iabsorption iby: A. Altering ithe ipH iof ithe istomach B. Increasing igastric iemptying itime C. Inhibiting iintestinal ienzymes irequired ifor ifolic iacid iabsorption D. Chelation iof ithe ifolic iacid iinto iinactive iingredients _ 12. iPatients itaking iwarfarin ineed ito ibe ieducated iabout ithe ivitamin iK icontent iof ifoods ito iavoid itherapeutic ifailure. iFoods ihigh iin ivitamin iK ithat ishould ibe ilimited ito ino imore ithan ione iserving iper iday iinclude: A. Spinach B. Milk C. Romaine ilettuce D. Cauliflower _ 13. iThe iAmerican iDietetic iAssociation i(ADA) ihas irecommended ithe iuse iof ispecific inutritional isupplements iin ithe ifollowing ipopulation(s): A. 400 iIU iper iday iof ivitamin iD iin iall iinfants iand ichildren B. 1000 iIU iper iday iof ivitamin iD ifor iall ipregnant iwomen C. 60 img iper iday iof iiron ifor iall iadults iover iage i50 iyears D. All iof ithe iabove _ 14. iThe iAmerican iDietetic iAssociation i(ADA) irecommends ipregnant iwome n itake ia isupplement iincluding: A. 1000 iIU idaily iof ivitamin iD B. 2.4 imcg/day iof ivitamin iB12 C. 600 imcg/day iof ifolic iacid D. 8 img/day iof iiron _ 15. iThe iAmerican iHeart iAssociation i(AHA) iand ithe iADA irecommend ia iminimum idaily ifiber iintake iof for icardiovascular ihealth: A. 10 img/day B. 15 img/day C. 20 img/day D. 25 img/day _ 16. iWhich iof ithe ifollowing ivitamin ior imineral isupplements imay iby iteratogenic iif ia ipregnant iwoman itakes imore ithan ithe irecommended iamount? A. Iron B. Vitamin iA C. Vitamin iB6 D. Vitamin iC _ 17. iVitamin iB2 i(riboflavin) imay ibe iprescribed ito: A. Decrease ithe iincidence iof iberiberi B. Reduce iheadaches iand imigraines C. Prevent ipernicious ianemia D. Treat ihyperlipidemia _ 18. iIsoniazid i(INH) imay iinduce ia ideficiency iof iwhich ivitamin? A. Vitamin iB6 B. Vitamin iC C. Vitamin iD D. Vitamin iE _ 19. iPregnant ipatients iwho iare itaking iisoniazid i(INH) ishould itake i25 img/day iof ivitamin iB6 i(pyridoxine) ito iprevent: A. Beriberi B. Peripheral ineuropathy C. Rickets D. Megaloblastic ianem ia _ 20. iVitamin iB12 ideficiency imay ilead ito: A. Hair iloss B. Insomnia C. Dry iscales ion ithe iscalp D. Numbness iand itingling iof ithe ihands _ 21. iSmokers iare iat irisk ifor ivitamin iC ideficiency. iIt iis irecommended ithat ismokers itake i i ivitamin iC isupplement. A. 100 img/day B. 500 img/day C. 1000 img/day D. 35 img/day imore ithan inonsmokers